NCT01695772View on ClinicalTrials.gov

A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 16, 2012

Primary Completion Date

April 4, 2015

Study Completion Date

May 12, 2016

Conditions
Colorectal Cancer
Interventions
DRUG

5-FU based doublet chemotherapy

Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.

DRUG

bevacizumab

5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

110042

Liaoning cancer Hospital & Institute, Shenyang

150001

The 2nd Affiliated Hospital of Harbin Medical University, Harbin

200032

Zhongshan Hospital Fudan University, Shanghai

310009

The Second Affiliated Hospital of Zhejiang University College, Hangzhou

430022

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan

510060

Sun Yet-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01695772 - A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer | Biotech Hunter | Biotech Hunter